1. Life Science Software: Markets and Opportunities
Report Details:
Published:September 2012
No. of Pages: 102
Price: Single User License – US$2430
Biopharm Reports has carried out six studies in the life science field, which examined the use of
specialist software and databases relating to the conduct of PCR, DNA sequencing, DNA
microarray, flow cytometry, mass spectrometry and disease biomarker studies. These studies,
which involved the participation of more than 2200 end-users in 70 countries, were carried out to
assist software developers and vendors to identify market opportunities in these fields.
Background
The last two decades have seen unprecedented advances in technologies and applications in the
life science field. Techniques such as PCR, DNA microarray, DNA sequencing, mass
spectrometry and flow cytometry have driven discoveries that have changed our understanding of
the world. Today, techniques such as these are indispensable to the laboratory and by 2015,
markets for these five areas alone are expected to exceed $50 billion, globally.
But, none of these developments would have been possible without parallel developments in
computing and software. Together they provide the systems that allow the high volumes of
complex information that these technologies generate, to be handled. Scientific and clinical needs
have driven the development of a multitude of data handling, software, databases and
bioinformatics platforms. But, despite the many products available, end-users are often restricted
in what they can do due to software limitations. Markets are also changing, which demand new
software solutions.
New Report
Biopharm Reports has published a new report on the use of software and databases in the life
science field. This is the outcome of six global studies involving more than 2,200 end-users in the
PCR, DNA microarray, DNA sequencing, mass spectrometry, flow cytometry and disease
biomarker fields. These finding provide substantial information on end-user practices and
opportunities in these markets.
This Report Provides:

2. •Software and Databases: A breakdown of end-user practices in the use of software and
databases (including software/database market brands or in-house) in the conduct of PCR, DNA
microarray, DNA sequencing, mass spectrometry, flow cytometry and disease biomarker studies.
•Fields: A breakdown of end-user practices in the use of software and databases (including
software/database market brands or in-house) by field (biotechnology, chemicals, clinical or
hospital, defence, diagnostics, energy, environmental, food and drink, forensics, geology,
government, healthcare, natural products, pharmaceuticals, research institutes, security and
university) in the conduct of PCR, DNA microarray, DNA sequencing, mass spectrometry, flow
cytometry and disease biomarker studies.
•Regions: A breakdown of end-user practices in the use of software and databases (including
software/database market brands or in-house) by regions (Europe, North America, Asia and Rest
of World) in the conduct of PCR, DNA microarray, DNA sequencing, mass spectrometry, flow
cytometry and disease biomarker studies.
•Growth: A listing of organisations of participants in the PCR, DNA microarray, DNA sequencing,
mass spectrometry, flow cytometry and disease biomarker studies described in this report,
according to their anticipated growth in these areas, (i.e. decline in activities, activities remain the
same or increase in activities).
•Market Sizes: Estimates of global markets sizes of software and databases used in the PCR,
DNA microarray, DNA sequencing, mass spectrometry, flow cytometry and disease biomarker
fields. These estimates are based on published market sizes of these fields, and the present
study findings described in this report.
Key Areas
PCR (Participants, n=614): Disclosures by experienced PCR end-users on their preferred
bioinformatics software in the PCR field (including market brands and in-house developed
systems); disclosures on the relative importance of specialist data control systems and/or
specialist bioinformatics systems, alongside ten other general areas, as areas where innovation is
most required in the PCR field; end-users' estimates of the breakdown of their current and future
(2012 - 2015) annual budgets in percentage terms across eight general areas, including control
and bioinformatics software, in the PCR field.
DNA Microarray (Participants, n=201): Disclosures by experienced microarray end-users (DNA
array, protein array, antibody array, tissue array) on their preferred bioinformatics software in the
PCR field (including market brands and in-house developed systems); end-users' disclosures on
the relative importance of specialist data control systems and/or specialist bioinformatics systems,
alongside ten other general areas, as areas where innovation is most required in the DNA
Microarray field; end-users' estimates of the breakdown of their current and future (2012 - 2015)
annual budgets in percentage terms across eight general areas, including control and
bioinformatics software, in the DNA microarray field.
DNA Sequencing (Participants, n=108): Disclosures by experienced DNA sequencers on their
preferred bioinformatics software in the DNA sequencing field (including market brands and in-
house developed systems); end-users' disclosures on the relative importance of specialist data
control systems and/or specialist bioinformatics systems, alongside ten other general areas, as

3. areas where innovation is most required in the DNA sequencing field; end-users' estimates of the
breakdown of their current and future (2012 - 2015) annual budgets in percentage terms across
eight general areas, including control and bioinformatics software, in the DNA sequencing field.
Flow Cytometry (Participants, n=262): Disclosures by experienced flow cytometry users on their
preferred data analysis (off line) software in the flow cytometry field; end-users' disclosures on the
relative importance of offline (analysis) software and/or online data handling software, alongside
eight other general areas, where innovation is most required in the flow cytometry field; end-users'
estimates of the breakdown of their current annual budgets in percentage terms across four
general areas, including system control and analysis (offline) software, in the mass spectrometry
field.
Mass Spectrometry (Participants, n=567): Disclosures by experienced mass spectrometrists on
their use (%) of data systems that are either part of the mass spectrometry systems supplied (i.e.
integrated data systems) or alternatively, data system that are installed independently (i.e.
independent data systems); type of independent data system used; type of database software
used in MS applications; use of other specialist software in MS applications; end-users'
disclosures on the relative importance of data systems/specialist software, alongside four other
general areas, where end-users anticipate the greatest innovation over the next three years; end-
users' estimates of the breakdown of their current annual budgets in percentage terms across four
general areas, including data handling and specialialist software, in the mass spectrometry field.
Disease Biomarkers (Participants n=511): Disclosures from scientists and clinicians on their two
main specialist software programs and their two main specialist databases, that provide the
greatest support to their work on disease biomarkers; disclosures on the relative importance of
specialist software and/or specialist databases and/or specialist data handling systems alongside
three other general areas, as areas where innovation is most required in the disease biomarker
field; End-users' estimates of the breakdown of their current annual budgets in percentage terms
across six general areas, including data handling, specialist software and databases, in the
disease biomarker field.
Participant Organisations: The names, countries and applications of participant organisations
Organisation Growth Trends: Organisations' reported plans in terms of growth in the area to
which the software and databases relate (i.e. decline in activities, activities remain the same or
increase in activities).
Get your copy of this report @
http://www.reportsnreports.com/reports/206077-life-science-software-markets-and-opportunities.html
Major points covered in Table of Contents of this report include
1 Background
2 This Study
3 Polymerase Chain Reaction (PCR)

4. 3.1 Study Questions
3.2 Participants
3.3 Organisations
3.4 Study Findings
3.5 Discussion
3.6 Conclusions
4 DNA Microarray
4.1 Study Questions
4.2 Participants
4.3 Organisations
4.4 Study Findings
4.5 Discussion
4.6 Conclusions
5 DNA Sequencing
5.1 Study Questions
5.2 Participants
5.3 Organisations
4.4 Study Findings
5.5 Discussion
5.6 Conclusions
6 Flow Cytometry
6.1 Study Questions
6.2 Participants
6.3 Organisations
6.4 Study Findings
6.5 Discussion
6.6 Conclusions
7 Mass Spectrometry
7.1 Study Questions
7.2 Participants
7.3 Organisations
7.4 Study Findings
7.5 Discussion
7.6 Conclusions
8 Disease Biomarkers
8.1 Study Questions
8.2 Participants

5. 8.3 Organisations
8.4 Study Findings
8.5 Discussion
8.6 Conclusions
9 Conclusions
Contact: sales@reportsandreports.com for more information.